Axsome Therapeutics Inc is trading 4.2% up today at $241.19 as investors react positively to the company's 2026 annual shareholder meeting and sustained bullish sentiment from analysts.
- The stock is significantly outperforming broader market indices, which are trading sharply lower, as focus remains on the company's growth pipeline and recent FDA-related progress.
- Wall Street price targets for the biopharmaceutical firm remain well above the current share price, further driving investor confidence in its long-term valuation.